Clinical Trial Update: Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating alpelisib with nab-paclitaxel in advanced triple-negative breast cancer with PIK3CA mutation or PTEN loss was terminated and results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Triple Negative Breast Neoplasms | Phase 3 | Status: TERMINATED | Results posted: 2024-07-31